Ann E. Berman
Ann E. Berman's purchase track record
Ann E. Berman has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/18/2024 | IMRX | $123K | -40.0% | +12.1% | +9.4% |
| 3/15/2022 | IMRX | $38K | -30.5% | +82.9% | -7.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Immuneering to Present Data at ESMO Congress 2026. Immuneering announced it will present data at the upcoming ESMO Congress in 2026. This event is relevant as it provides a future opportunity for the company to share clinical updates with the medical community. The stock is currently trading below its 52-week high, with analysts maintaining a wide range of price targets.
Transaction History
| L | ▲ Buy | Grant | 235 | $0 | 3/31/2026 | View on chart |
| L | ▼ Sell | Open Market | 1,922 | $212K | 2/10/2026 | View on chart |
| L | ▲ Buy | Grant | 234 | $0 | 12/31/2025 | View on chart |
| L | ▼ Sell | Open Market | 1,444 | $156K | 12/1/2025 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $87K | 12/1/2025 | View on chart |
| L | ▼ Sell | Other | 806 | $87K | 12/1/2025 | View on chart |
| L | ▲ Buy | Grant | 251 | $0 | 9/30/2025 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $80K | 9/2/2025 | View on chart |
| L | ▼ Sell | Other | 828 | $80K | 9/2/2025 | View on chart |
| L | ▼ Sell | Open Market | 1,422 | $137K | 9/2/2025 | View on chart |
| L | ▲ Buy | Grant | 149 | $0 | 6/30/2025 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $87K | 6/2/2025 | View on chart |
| L | ▼ Sell | Other | 977 | $87K | 6/2/2025 | View on chart |
| L | ▼ Sell | Open Market | 1,273 | $113K | 6/2/2025 | View on chart |
| L | ▲ Buy | Option Exercise | 1,288 | $0 | 5/14/2025 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $91K | 3/3/2025 | View on chart |
| L | ▼ Sell | Other | 1,053 | $91K | 3/3/2025 | View on chart |
| L | ▼ Sell | Open Market | 1,197 | $104K | 3/3/2025 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $96K | 12/2/2024 | View on chart |
| L | ▼ Sell | Open Market | 1,146 | $99K | 12/2/2024 | View on chart |
| L | ▼ Sell | Other | 1,104 | $96K | 12/2/2024 | View on chart |
| L | ▼ Sell | Other | 1,163 | $95K | 9/3/2024 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $94K | 9/3/2024 | View on chart |
| L | ▼ Sell | Open Market | 1,087 | $88K | 9/3/2024 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $99K | 6/3/2024 | View on chart |
| L | ▼ Sell | Other | 1,287 | $99K | 6/3/2024 | View on chart |
| L | ▼ Sell | Open Market | 963 | $73K | 6/3/2024 | View on chart |
| L | ▲ Buy | Option Exercise | 1,706 | $0 | 5/9/2024 | View on chart |
| IMRX | ▲ Buy | Open Market | 57,965 | $123K | 3/18/2024 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $98K | 3/1/2024 | View on chart |
| L | ▼ Sell | Other | 1,299 | $98K | 3/1/2024 | View on chart |
| L | ▼ Sell | Open Market | 951 | $71K | 3/1/2024 | View on chart |
| L | ▼ Sell | Other | 1,535 | $108K | 12/1/2023 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $108K | 12/1/2023 | View on chart |
| L | ▼ Sell | Open Market | 715 | $50K | 12/1/2023 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $106K | 9/1/2023 | View on chart |
| L | ▼ Sell | Other | 1,689 | $106K | 9/1/2023 | View on chart |
| L | ▼ Sell | Open Market | 561 | $35K | 9/1/2023 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $100K | 6/1/2023 | View on chart |
| L | ▼ Sell | Other | 1,776 | $100K | 6/1/2023 | View on chart |
| L | ▼ Sell | Open Market | 474 | $27K | 6/1/2023 | View on chart |
| L | ▲ Buy | Option Exercise | 1,567 | $0 | 5/10/2023 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $99K | 3/1/2023 | View on chart |
| L | ▼ Sell | Other | 1,625 | $99K | 3/1/2023 | View on chart |
| L | ▼ Sell | Open Market | 625 | $38K | 3/1/2023 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $91K | 12/1/2022 | View on chart |
| L | ▼ Sell | Open Market | 698 | $40K | 12/1/2022 | View on chart |
| L | ▼ Sell | Other | 1,552 | $91K | 12/1/2022 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $93K | 9/1/2022 | View on chart |
| L | ▼ Sell | Open Market | 572 | $31K | 9/1/2022 | View on chart |
| L | ▼ Sell | Other | 1,678 | $93K | 9/1/2022 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $90K | 6/1/2022 | View on chart |
| L | ▼ Sell | Open Market | 883 | $57K | 6/1/2022 | View on chart |
| L | ▼ Sell | Other | 1,367 | $90K | 6/1/2022 | View on chart |
| L | ▲ Buy | Option Exercise | 1,725 | $0 | 5/11/2022 | View on chart |
| IMRX | ▲ Buy | Open Market | 6,000 | $38K | 3/15/2022 | View on chart |
| L | ▲ Buy | Option Exercise | 2,250 | $89K | 3/1/2022 | View on chart |
| L | ▼ Sell | Other | 1,453 | $89K | 3/1/2022 | View on chart |
| L | ▼ Sell | Open Market | 797 | $48K | 3/1/2022 | View on chart |
| L | ▲ Buy | Option Exercise | 1,500 | $57K | 12/1/2021 | View on chart |
| L | ▼ Sell | Other | 1,041 | $57K | 12/1/2021 | View on chart |
| L | ▼ Sell | Open Market | 459 | $25K | 12/1/2021 | View on chart |
| L | ▲ Buy | Option Exercise | 1,500 | $53K | 9/1/2021 | View on chart |
| L | ▼ Sell | Other | 939 | $53K | 9/1/2021 | View on chart |
| L | ▼ Sell | Open Market | 561 | $31K | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Loews Stock Valuation Reviewed After 92% Five-Year Gain
Recent analysis suggests Loews stock appears reasonably valued following a 92% increase over the past five years. This long-term performance provides context for the current share price within its 52-week range. The commentary focuses on the stock's historical growth rather than immediate short-term movements.
Loews Stock Valuation Reviewed After 92% Five-Year Gain. Recent analysis suggests Loews stock appears reasonably valued following a 92% increase over the past five years. This long-term performance provides context for the current share price within its 52-week range. The commentary focuses on the stock's historical growth rather than immediate short-term movements.